Latest Us Market News

HighCom Limited has revealed a sharp downturn in its half-year results, with revenue plunging 59% and a $6.8 million loss after tax, driven by US government shutdown impacts. The company is banking on new lightweight XTclave® armour products to fuel a recovery in the second half of FY26.

Bubs Australia has delivered a robust first half for FY26, powered by a 48% revenue surge in the US, prompting an upgrade to its full-year earnings guidance.

BetMakers Technology Group Ltd reported an 11.4% rise in half-year revenue to $46.1 million alongside a dramatic 80% reduction in losses, setting the stage for accelerated global growth and a strategic US market push.

DorsaVi Limited reported a steep increase in its half-year loss to $3.6 million, driven by declining revenues and a sharp rise in operating costs, despite raising over $5 million in fresh capital.

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.

Ovanti Limited announces a strategic leadership change in its US operations to boost its BNPL platform Flote’s commercialisation and prepare for a potential NASDAQ listing via SPAC.

StepChange Holdings Limited reports a strong half-year performance post-IPO, with $24.36 million in revenue and a net profit of $524,400, underpinned by key acquisitions and US expansion.

TZ Limited reported a $1.92 million loss for the half-year ending December 2025, with revenues of $5.4 million impacted by delayed US projects and integration challenges from its Keyvision acquisition. The company is banking on large tenders and expanding Microsoft data centre sales to drive recovery.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Cettire Limited reported a 2.8% revenue decline to $382.8 million and a net loss of $1.05 million for the half-year ended 31 December 2025, impacted by softer US demand and rising costs. Despite these headwinds, the company maintains a strong cash position and is focused on profitable growth.

Tungsten Mining is pursuing a US stock exchange listing to tap into deeper capital markets and strengthen ties with US government and industry stakeholders, complementing its existing ASX listing.